Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | PTGIR | P43119 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101932 | 0.76 | CYP11B2 (0.39) | CYP11B2PTGIRSMN1; SMN2DRD4DRD3 | |
| SCHEMBL12175373 | 0.71 | CREBBP (0.62) | CYP11B2SMN1; SMN2DRD4DRD3DRD2 | |
| SCHEMBL10555147 | 0.71 | PTGIR (0.55) | CYP11B2PTGIRSMN1; SMN2GAAMAPT | |
| SCHEMBL103215 | 0.70 | PTGIR (0.39) | PTGIRSMN1; SMN2DRD4DRD3DRD2 | |
| SCHEMBL12985515 | 0.70 | SMN1; SMN2 (0.54) | CYP11B2PTGIRSMN1; SMN2DRD4DRD3 | |
| SCHEMBL103799 | 0.68 | CYP1A2 (0.71) | SMN1; SMN2RAB9ANPC1L3MBTL1CYP1A2 | |
| SCHEMBL102258 | 0.67 | L3MBTL1 (0.56) | CREBBPRAB9AMAPTL3MBTL1 | |
| SCHEMBL11699508 | 0.67 | CYP1A2 (0.51) | PTGIRSMN1; SMN2GAARAB9ANPC1 | |
| SCHEMBL9045659 | 0.66 | HTR1A (0.57) | DRD4DRD3DRD2CYP1A2ALDH1A1 | |
| SCHEMBL25256950 | 0.66 | TSHR (0.55) | CYP11B2SMN1; SMN2DRD4DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | CYP11B2 2341/4885PTGIR 647/4885SMN1; SMN2 881/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | CYP11B2 2095/4885PTGIR 614/4885SMN1; SMN2 1094/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | CYP11B2 2341/4885PTGIR 647/4885SMN1; SMN2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.